DSIP vs Navepegritide

Overview

DSIP is primarily a sleep & recovery peptide, while Navepegritide is used for bone & joint.

This page compares DSIP and Navepegritide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. DSIP is categorised under Sleep & Recovery, while Navepegritide falls under Bone & Joint. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. DSIP: not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it. Navepegritide: FDA-approved.

Dosing. DSIP is typically dosed at 100-300 mcg (before bed). Typical dosing for Navepegritide is not catalogued.

Can you stack them?

Some protocols combine peptides, but stacking DSIP and Navepegritide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between DSIP and Navepegritide?

DSIP is primarily a sleep & recovery peptide, while Navepegritide is used for bone & joint. DSIP is not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it, whereas Navepegritide is FDA-approved for one or more indications.

What is DSIP used for?

Delta sleep-inducing peptide.

What is Navepegritide used for?

PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026.

Can you take DSIP and Navepegritide together?

Some users combine peptides within a single protocol, but stacking DSIP and Navepegritide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is DSIP or Navepegritide FDA-approved?

DSIP is not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it. Navepegritide is FDA-approved for one or more indications.